[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Takahashi
Shin'ichi
S
Third Department of Internal Medicine, Kyorin University School of Medicine.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D002986:Clinical Trials as Topic; D004415:Dyspepsia / Q000382:microbiology; D005756:Gastritis / Q000382:microbiology; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D018442:Lymphoma, B-Cell, Marginal Zone / Q000382:microbiology; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000382:microbiology; D013274:Stomach Neoplasms / Q000382:microbiology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D009853:Omeprazole